JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB312374

重组Alexa Fluor® 568荧光Anti-LMO2抗体[SP51] - N-terminal

Alexa Fluor® 568 Anti-LMO2 antibody [SP51] - N-terminal

Be the first to review this product! Submit a review

|

(0 Publication)

Rabbit Recombinant Monoclonal LMO2 antibody - conjugated to Alexa Fluor® 568.

查看别名

RBTN2, RBTNL1, RHOM2, TTG2, LMO2, Rhombotin-2, Cysteine-rich protein TTG-2, LIM domain only protein 2, T-cell translocation protein 2, LMO-2

不同偶联物与剂型 (9)

  • 578 PE

    PE Anti-LMO2 antibody [SP51] (N-terminal)

  • 660 APC

    APC Anti-LMO2 antibody [SP51] (N-terminal)

  • HRP

    HRP Anti-LMO2 antibody [SP51] (N-terminal)

  • 665 Alexa Fluor® 647

    Alexa Fluor® 647 Anti-LMO2 antibody [SP51] - N-terminal

  • 617 Alexa Fluor® 594

    Alexa Fluor® 594 Anti-LMO2 antibody [SP51] - N-terminal

  • 565 Alexa Fluor® 555

    Alexa Fluor® 555 Anti-LMO2 antibody [SP51] - N-terminal

  • 775 Alexa Fluor® 750

    Alexa Fluor® 750 Anti-LMO2 antibody [SP51] - N-terminal

  • Unconjugated

    Anti-LMO2 antibody [SP51] - N-terminal

  • Carrier free

    Anti-LMO2 antibody [SP51] - BSA and Azide free

关键信息

宿主种属

Rabbit

克隆

Monoclonal

克隆号

SP51

亚型

IgG

偶联物

Alexa Fluor® 568

激发波长/发射波长

Ex: 578nm, Em: 603nm

不含载体蛋白

No

应用

Target Binding Affinity, Antibody Labelling

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

产品详情

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

性能和储存信息

形式
Liquid
纯化工艺
Affinity purification Protein A
存储溶液
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
运输条件
Blue Ice
推荐的短期储存时间
1-2 weeks
推荐的短期储存条件
+4°C
推荐的长期储存条件
-20°C
分装信息
Upon delivery aliquot
储存信息
Avoid freeze / thaw cycle|Store in the dark

补充信息

This supplementary information is collated from multiple sources and compiled automatically.

LMO2 also known as LIM Domain Only 2 is a transcription factor with a molecular weight of approximately 24 kDa. It contains two LIM domains which enable protein-protein interactions. LMO2 expression is mostly found in hematopoietic tissues and the vascular endothelium. This protein does not directly bind DNA but forms complexes with other proteins to exert its regulatory roles.
Biological function summary

This transcription factor is important in hematopoiesis and angiogenesis. LMO2 forms multiprotein complexes that include TAL1 GATA1 and E47 which are necessary for the transcriptional activation of genes involved in blood cell differentiation and formation. Its role in angiogenesis involves participating in the transcriptional regulation of genes essential for blood vessel formation.

Pathways

LMO2 plays a significant role in the development of the hematopoietic system and vascular network. It is part of the TAL1-LMO2-LDB1 transcriptional complex within the hematopoietic transcriptional network which includes other key proteins like GATA1 and E47. These pathways ensure proper development and differentiation of various blood cell lineages and endothelial cells.

LMO2 has a known association with T-cell acute lymphoblastic leukemia (T-ALL) and some other hematological malignancies. Abnormal expression of LMO2 can lead to oncogenic transformation in hematopoietic cells. Within these disease contexts LMO2 interacts with proteins like TAL1 and LDB1 contributing to leukemogenic processes. Understanding its role helps in the development of therapeutic strategies targeting these pathways.

产品实验方案

For this product, it's our understanding that no specific protocols are required. You can visit:

靶点信息

Acts with TAL1/SCL to regulate red blood cell development. Also acts with LDB1 to maintain erythroid precursors in an immature state.
See full target information LMO2

Abcam Product Promise

我们致力于为您的研究提供高质量的试剂,为您科研的每一步提供支持。若我们的产品未能达到预期性能,我们向您提供 Abcam Product Promise 保障。
详情请参阅我们的条款与条件。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com